Replies to post #92742 on $heff's $tation of $tocks & $olid DD

[kklar1]

$PETX $2.80 Bought another tranche in this name as it moves south with the rest of the market. Should be in a good position to recover into it's catalyst:

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the Company filed an administrative New Animal Drug Application (NADA) with the Food and Drug Administration's Center for Veterinary Medicine (CVM) for Galliprant® for the control of pain and inflammation in dogs with osteoarthritis. The Animal Drug User Fee Act (ADUFA) date for approval is set for March 25.